Alivus Targets 30–32% EBITDA Margin Despite PLI Loss
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) — Q4 & FY26 Earnings Call (Quarter ended Mar 31, 2026) 1. Overall Tone of Management: Optimistic Management highlights “strong and consistent performance” and “meaningfully improved the…
